West Nile Virus M glycoprotein peptide (ab39904)

Overview

  • Product nameWest Nile Virus M glycoprotein peptide

Description

  • NatureSynthetic

Specifications

Our Abpromise guarantee covers the use of ab39904 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking

    ELISA

  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: 0.02% Sodium Azide
    Constituents: 0.1% BSA, PBS, pH 7.2

General Info

  • Alternative names
    • Envelope protein M
    • Matrix protein
    • West Nile virus matrix protein
    • WNV matrix protein
  • RelevanceWest Nile (WN), the most widespread among flaviviruses, was first isolated from the serum of a febrile woman in 1937 in the West Nile district of Uganda. West Nile virus was first detected in North America in 1999 and has subsequently spread throughout the United States and Canada and into Mexico and the Caribbean. In Africa, southern Europe, western Asia, and the United States, WNV has been isolated from mosquitoes of more than 40 species. In the United States, Canada, and Israel, WNV is responsible for significant avian mortality.

References for West Nile Virus M glycoprotein peptide (ab39904)

ab39904 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab39904.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"